logo-loader
viewMorgan Stanley

Morgan Stanley downgrades Tesla to Underweight with unchanged target price of $360

The investment bank said it based its decision on valuation, unfavorable risk-reward, and risks to the long-term Chinese business that may not be fully appreciated by the market

Morgan Stanley - Morgan Stanley downgrades Tesla Inc to Underweight from Equal-weight with an unchanged target price of $360
Tesla’s stock trades around $502 a share in New York

Morgan Stanley (NYSE:MS) has downgraded its rating for Tesla Inc (NASDAQ:TSLA) shares to Underweight from Equal-weight with an unchanged target price of $360.

The investment bank said it based its decision on valuation, unfavorable risk-reward, and risks to Tesla's long-term Chinese business that may not be fully appreciated by the market.

READ: Tesla to dish out US$346mln pay package for Elon Musk

Morgan Stanley wrote: “In our opinion, four factors have driven TSLA's share price up more than 105% over the last four months versus more than 10% for S&P 500: (1) stronger than expected global demand for Tesla vehicles, which has created more optimism around the long-term margin profile of the business; (2) China announcements that show Tesla's expansion into the world's largest electric vehicle market is progressing well from a demand and margin perspective; (3) supportive incentive developments (i.e. the potential, however small, for extended subsidies in the US); and (4) positive sentiment around product expansion.” 

The bank said that these factors “have triggered a significant reduction in the market's implied risk premium for this asset. Near-term momentum and sentiment around the stock is admittedly very strong, but we ultimately question the sustainability of the momentum.”

Tesla’s stock recently traded down 3% to $502 a share in New York.

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

 

Quick facts: Morgan Stanley

Price: 55.84 USD

NYSE:MS
Market: NYSE
Market Cap: $89.01 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Genprex sees newly licensed diabetes gene therapy as an...

Genprex Inc (NASDAQ:GNPX) CEO Rodney Varner tells Proactive the Texas-based biotech has signed a licensing agreement with the University of Pittsburgh for a diabetes gene therapy that could have the potential to treat Type 1 and Type 2 diabetes. Varner says the newly licensed diabetes gene...

2 days, 14 hours ago

2 min read